Project Grant R43NS110117

This Project Grant award of $455,371 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development and validation of a novel microchip-based platform for the discovery and characterization of migraine therapies. The key products and services to be delivered under this award include: Quantifying comprehensive neurovascular and behavioral responses to established migraine triggers and...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,375.00 to support research on the role of the GPR37L1 receptor in chronic migraine. The funding will enable a research team at Florida Atlantic University, with a sub-award to the University of Florida, to conduct a comprehensive investigation into the involvement of GPR37L1 signaling in the neuropathology of...

The National Institutes of Health National Center for Complementary and Integrative Health awarded New York University $785,637 under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) from June 2021 through May 2025. This Cooperative Agreement will support the development and pilot testing of telephone-delivered and video-based Mindfulness-Based Cognitive Therapy (MBCT) protocols for patients with migraine headaches and depressive symptoms. Specifically, the...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA Program 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders", provides $620,278 to the University of Maryland, Baltimore to investigate the molecular basis for using sphingosine-1-phosphate receptor 1 (S1PR1) antagonists to treat the comorbid conditions of migraine and temporomandibular disorders (TMDs). The research aims to establish...

The National Institute of Mental Health (NIMH) awarded a $370,440 Project Grant under CFDA 93.242 (Mental Health Research Grants) to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System Incorporated, to conduct research on the longitudinal association between migraine and affective disorders across the lifespan, with a focus on hormonal fluctuations. The key objectives of this 4-year research project are to: Determine the longitudinal relationship between migraine and...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...

This federal Project Grant award of $475,475 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award will support research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate the role of circadian-driven complement activation and purinergic signaling as potential triggers of morning migraine. The research aims to define the...

The National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health, awarded a $1,060,060 Cooperative Agreement (Federal Grant ID: U01AT012611) to Brigham & Women's Hospital Inc. to conduct a 3-year pilot study on the use of cocoa flavanols for migraine treatment. The study aims to assess the feasibility of recruitment, retention, and adherence, determine the acceptability of higher doses of cocoa extract supplements, and optimize data collection...

This Project Grant award from the National Institute of Child Health and Human Development, under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to develop a transdermal patch for the treatment of pregnancy-induced nausea and vomiting (PINV). The $333,284 award to Integurx Therapeutics LLC will fund efforts to optimize the product design, produce pilot-scale patches, and conduct safety studies for a novel transdermal delivery system of the anti-nausea drug...

This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $818,360 to the University of Southern California (USC) to develop new angiotensin AT2 receptor inhibitors for the treatment of neuropathic pain. The project aims to optimize lead compounds that have demonstrated efficacy in preclinical models, with a focus on eliminating a...